Stock Events

Stock Events

Faron Pharmaceuticals Oy 

GBX44.9
10
+GBX2.35+5.52% Today

Statistics

Day High
44.9
Day Low
40
52W High
252.5
52W Low
38.7
Volume
495,718
Avg. Volume
-
Mkt Cap
50.27M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4MarExpected
Q4 2022
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-18.54
-12.46
-6.38
-0.3
Expected EPS
-8.808326156240248
Actual EPS
-5.98259790491115

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-4.32BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FARN.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. competes in the biopharmaceutical sector focusing on antiviral drugs, a similar therapeutic area to Faron's focus on immune modulation and cancer.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. is a biotech firm that develops innovative therapeutics in areas like oncology, competing with Faron's cancer treatment research.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals, Inc. is involved in immunology and oncology, directly competing with Faron's research in immune modulation and cancer treatments.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. has a broad portfolio including cancer treatments, directly competing with Faron's oncology research.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb Company operates in the oncology space, making it a competitor to Faron's cancer treatment developments.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. has a diverse biopharmaceutical portfolio including oncology and immunology, overlapping with Faron's research areas.
Novartis
NVS
Mkt Cap279.67B
Novartis AG focuses on innovative medicines in areas including oncology, competing with Faron's cancer research.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG specializes in pharmaceuticals and diagnostics in oncology and immunology, competing with Faron's therapeutic areas.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca PLC has a strong focus on oncology and respiratory diseases, overlapping with Faron's research interests.
Sanofi
SNY
Mkt Cap110.4B
Sanofi operates in core therapeutic areas that include oncology, making it a competitor to Faron Pharmaceuticals in the cancer treatment market.

About

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Show more...
CEO
Dr. Juho Markku Jalkanen M.D., MSc, Ph.D.
Employees
33
Country
Finland
ISIN
FI4000153309

Listings

HE
FI
FARON.HE
LSE
GB
FARN.LSE
F
DE
4FR.F

0 Comments

Share your thoughts

FAQ

What is Faron Pharmaceuticals Oy stock price today?▼
The current price of FARN.LSE is GBX44.9 GBX — it has increased by +5.52% in the past 24 hours. Watch Faron Pharmaceuticals Oy stock price performance more closely on the chart.
What is Faron Pharmaceuticals Oy stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Faron Pharmaceuticals Oy stocks are traded under the ticker FARN.LSE.
Is Faron Pharmaceuticals Oy stock price growing?▼
FARN.LSE stock has risen by +9.98% compared to the previous week, the month change is a -8.35% fall, over the last year Faron Pharmaceuticals Oy has showed a -77.87% decrease.
What is Faron Pharmaceuticals Oy market cap?▼
Today Faron Pharmaceuticals Oy has the market capitalization of 50.27M
When is the next Faron Pharmaceuticals Oy earnings date?▼
Faron Pharmaceuticals Oy is going to release the next earnings report on August 26, 2026.
What were Faron Pharmaceuticals Oy earnings last quarter?▼
FARN.LSE earnings for the last quarter are -5.98 GBX per share, whereas the estimation was -8.81 GBX resulting in a +32.08% surprise. The estimated earnings for the next quarter are N/A GBX per share.
What is Faron Pharmaceuticals Oy revenue for the last year?▼
Faron Pharmaceuticals Oy revenue for the last year amounts to 0 GBX.
What is Faron Pharmaceuticals Oy net income for the last year?▼
FARN.LSE net income for the last year is -4.32B GBX.
How many employees does Faron Pharmaceuticals Oy have?▼
As of May 05, 2026, the company has 33 employees.
In which sector is Faron Pharmaceuticals Oy located?▼
Faron Pharmaceuticals Oy operates in the Health & Wellness sector.
When did Faron Pharmaceuticals Oy complete a stock split?▼
Faron Pharmaceuticals Oy has not had any recent stock splits.
Where is Faron Pharmaceuticals Oy headquartered?▼
Faron Pharmaceuticals Oy is headquartered in Turku, Finland.